Table 3

Malignancies in the PsABio population distinguished by time period since treatment initiation (safety set)

0–6 months (n=457)7–12 months (n=467)>12 months* (n=494)0–6 months (n=489)7–12 months (n=502)>12 months* (n=557)
n (%)3 (0.6)2 (0.4)3 (0.6)2 (0.4)3 (0.6)4 (0.7)
EventsCutaneous T-cell lymphoma
Parathyroid tumour
Bowen’s disease
Lung neoplasm
Colon cancer
Malignant neoplasm of eye
Prostate cancer
Lung adenocarcinoma
Myelodysplastic syndrome
Renal oncocytoma
Basal cell carcinoma
Squamous cell carcinoma
Bladder neoplasm
Colon cancer
Malignant urinary tract neoplasm
Squamous cell carcinoma
  • The total number of patients is higher than the number in the full analysis set because the same patients were included several times for adverse event evaluation if they were switchers.

  • *Usually only malignancies diagnosed after a lag time of 12 months are attributable to a newly initiated treatment.

  • TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.